In the AWARD programme, the proportion of adults reaching the composite endpoint at 26 weeks did not differ between dulaglutide 1.5 mg and liraglutide 1.8 mg.
In plain wordsLiraglutide 1.8 mg and dulaglutide 1.5 mg were equally likely to reach the combined blood sugar, weight and hypoglycaemia target.
- Peptide
- Liraglutide
- Outcome
- No significant changeComposite endpoint (HbA1c <7.0%, no weight gain, no hypoglycaemia) at 26 weeks, liraglutide 1.8 mg versus dulaglutide 1.5 mg
- Study
n: not reported in source
- Comparator
- Dulaglutide 1.5 mg
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 1.8 mg · 26 weeksAs given in this study (human).
Source sentences
with no difference between dulaglutide 1.5 mg and liraglutide 1.8 mg.
1 context sentence(design, population, supporting numbers)
A logistic regression analysis was performed on the intention-to-treat population, using data from the last observation carried forward, and the composite endpoint of HbA1c <7.0% (53 mmol/mol), no weight gain (≤0 kg) and no hypoglycaemia (glucose <3.0 mmol/l or severe hypoglycaemia) after 26 weeks f…